Joachim Sieper

75.4k total citations · 14 hit papers
551 papers, 37.6k citations indexed

About

Joachim Sieper is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Joachim Sieper has authored 551 papers receiving a total of 37.6k indexed citations (citations by other indexed papers that have themselves been cited), including 515 papers in Rheumatology, 257 papers in Immunology and 133 papers in Hematology. Recurrent topics in Joachim Sieper's work include Spondyloarthritis Studies and Treatments (478 papers), Rheumatoid Arthritis Research and Therapies (358 papers) and Psoriasis: Treatment and Pathogenesis (224 papers). Joachim Sieper is often cited by papers focused on Spondyloarthritis Studies and Treatments (478 papers), Rheumatoid Arthritis Research and Therapies (358 papers) and Psoriasis: Treatment and Pathogenesis (224 papers). Joachim Sieper collaborates with scholars based in Germany, United States and Netherlands. Joachim Sieper's co-authors include Jürgen Braun, Martín Rudwaleit, Joachim Listing, Désirée van der Heijde, Denis Poddubnyy, Xenofon Baraliakos, Hildrun Haibel, J. Brandt, Maxime Dougados and Kay‐Geert Hermann and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Joachim Sieper

527 papers receiving 36.3k citations

Hit Papers

Ankylosing spondylitis 1998 2026 2007 2016 2007 2009 2010 2002 2017 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ankylosing spondylitis
    2007 1.4k citations Jürgen Braun, Joachim Sieper The Lancet profile →
  2. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis
    2009 1.2k citations Joachim Sieper, Martín Rudwaleit et al. Annals of the Rheumatic Diseases profile →
  3. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
    2010 1.1k citations Martín Rudwaleit, D. van der Heijde et al. Annals of the Rheumatic Diseases profile →
  4. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial
    2002 953 citations Jürgen Braun, J. Brandt et al. The Lancet profile →
  5. Axial spondyloarthritis
    2017 871 citations Joachim Sieper, Denis Poddubnyy The Lancet profile →
  6. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
    2015 732 citations Dominique Baeten, Joachim Sieper et al. profile →
  7. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis
    2008 720 citations Robert Landewé, Joachim Sieper et al. Annals of the Rheumatic Diseases profile →
  8. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors
    1998 699 citations Martín Rudwaleit, Joachim Sieper et al. profile →
  9. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial
    2006 660 citations Désirée van der Heijde, Joachim Sieper et al. profile →
  10. Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo‐controlled trial (ASSERT)
    2005 651 citations Désirée van der Heijde, Joachim Sieper et al. profile →
  11. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group
    2009 649 citations Martín Rudwaleit, R. B. M. Landewé et al. Annals of the Rheumatic Diseases profile →
  12. The early disease stage in axial spondylarthritis: Results from the german spondyloarthritis inception cohort
    2009 512 citations Martín Rudwaleit, Hildrun Haibel et al. profile →
  13. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis
    2008 455 citations Désirée van der Heijde, Joachim Sieper et al. Annals of the Rheumatic Diseases profile →
  14. Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double‐blind, placebo‐controlled, phase III trial
    2008 444 citations Robert D. Inman, John C. Davis et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joachim Sieper Germany 101 32.8k 18.7k 11.0k 4.7k 3.1k 551 37.6k
Jürgen Braun Germany 90 27.3k 0.8× 15.0k 0.8× 9.0k 0.8× 4.1k 0.9× 2.2k 0.7× 583 31.4k
Walter P. Maksymowych Canada 70 14.4k 0.4× 6.9k 0.4× 4.5k 0.4× 4.2k 0.9× 1.8k 0.6× 520 18.0k
Martín Rudwaleit Germany 71 17.1k 0.5× 9.0k 0.5× 5.2k 0.5× 3.0k 0.6× 1.4k 0.4× 310 18.8k
Jane G. Schaller United States 32 23.7k 0.7× 10.5k 0.6× 6.2k 0.6× 800 0.2× 3.2k 1.0× 91 33.2k
Robert D. Inman Canada 65 9.3k 0.3× 5.9k 0.3× 3.4k 0.3× 1.1k 0.2× 2.1k 0.7× 368 14.5k
John D. Reveille United States 79 14.3k 0.4× 9.0k 0.5× 3.1k 0.3× 563 0.1× 2.1k 0.7× 384 21.3k
Dominique Baeten Netherlands 71 9.8k 0.3× 8.2k 0.4× 3.8k 0.3× 654 0.1× 2.5k 0.8× 321 16.1k
Larry W. Moreland United States 59 12.2k 0.4× 4.7k 0.3× 5.0k 0.5× 445 0.1× 1.8k 0.6× 291 18.9k
Thomas A. Medsger United States 85 19.5k 0.6× 10.0k 0.5× 4.1k 0.4× 821 0.2× 4.3k 1.4× 229 43.1k
Ricard Cervera Spain 79 21.8k 0.7× 8.4k 0.5× 7.4k 0.7× 237 0.1× 1.7k 0.6× 562 29.5k

Countries citing papers authored by Joachim Sieper

Since Specialization
Citations

This map shows the geographic impact of Joachim Sieper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joachim Sieper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joachim Sieper more than expected).

Fields of papers citing papers by Joachim Sieper

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joachim Sieper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joachim Sieper. The network helps show where Joachim Sieper may publish in the future.

Co-authorship network of co-authors of Joachim Sieper

This figure shows the co-authorship network connecting the top 25 collaborators of Joachim Sieper. A scholar is included among the top collaborators of Joachim Sieper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joachim Sieper. Joachim Sieper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heijde, Désirée van der, Victoria Navarro‐Compán, R. Landewé, et al.. (2025). 1995-2025: thirty years of ASAS and its contribution to the understanding of spondyloarthritis. Annals of the Rheumatic Diseases. 84(3). 382–387.
2.
López‐Medina, Clementina, Désirée van der Heijde, Robert Landewé, et al.. (2025). Evaluation of instruments assessing peripheral arthritis in spondyloarthritis: an analysis of the ASAS-PerSpA study. Annals of the Rheumatic Diseases. 84(8). 1324–1334. 2 indexed citations
3.
Rodríguez, Valeria Ríos, Murat Torğutalp, Fabian Proft, et al.. (2024). Impact of body composition on clinical outcomes in patients with active radiographic axial spondyloarthritis under biological therapy. Lara D. Veeken. 64(3). 1162–1169.
4.
Rodríguez, Valeria Ríos, Hildrun Haibel, Mikhail Protopopov, et al.. (2024). Association of nociplastic and neuropathic pain components with the presence of residual symptoms in patients with axial spondyloarthritis receiving biological disease-modifying antirheumatic drugs. RMD Open. 10(1). e004009–e004009. 11 indexed citations
5.
Braun, Jürgen, Elisabeth Märker‐Hermann, Martín Rudwaleit, & Joachim Sieper. (2024). HLA-B27 and the role of specific T cell receptors in the pathogenesis of spondyloarthritis. Annals of the Rheumatic Diseases. 83(11). 1406–1408. 2 indexed citations
6.
Torğutalp, Murat, Valeria Ríos Rodríguez, Fabian Proft, et al.. (2022). Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis. Annals of the Rheumatic Diseases. 81(9). 1252–1259. 12 indexed citations
7.
Poddubnyy, Denis, Fabian Proft, Laura Spiller, et al.. (2021). Diagnosing axial spondyloarthritis: estimation of the disease probability in patients witha prioridifferent likelihoods of the diagnosis. Lara D. Veeken. 60(11). 5098–5104. 9 indexed citations
8.
Rodríguez, Valeria Ríos, Mikhail Protopopov, Joachim Sieper, et al.. (2020). Assessment of radiographic sacroiliitis in anteroposterior lumbar vs conventional pelvic radiographs in axial spondyloarthritis. Lara D. Veeken. 60(1). 269–276. 5 indexed citations
9.
López‐Medina, Clementina, Sofía Ramiro, Désirée van der Heijde, et al.. (2019). Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis. RMD Open. 5(2). e001108–e001108. 84 indexed citations
10.
11.
Maksymowych, Walter P., Maxime Dougados, Désirée van der Heijde, et al.. (2015). Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. Annals of the Rheumatic Diseases. 75(7). 1328–1335. 80 indexed citations
12.
Kiltz, Uta, Martín Rudwaleit, Joachim Sieper, & Joseph M. Braun. (2014). DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen. Zeitschrift für Rheumatologie. 73(S2). 40–43.
13.
Emery, P., Dominique Baeten, Joachim Sieper, et al.. (2012). EVALUATION OF EFFICACY AND SAFETY OF SECUKINUMAB IN THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE ANKYLOSING SPONDYLITIS. Lara D. Veeken. 51. 21–21. 6 indexed citations
14.
Rudwaleit, Martín, D. van der Heijde, R. B. M. Landewé, et al.. (2010). The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Annals of the Rheumatic Diseases. 70(1). 25–31. 1135 indexed citations breakdown →
15.
Heijde, D. van der, Atul Deodhar, Laura Diekman, et al.. (2010). GOLIMUMAB, A NEW HUMAN TNF-alpha ANTIBODY ADMINISTERED SUBCUTANEOUSLY EVERY 4 WEEKS, IN ANKYLOSING SPONDYLITIS : 104-WEEK EFFICACY AND SAFETY RESULTS OF THE RANDOMIZED, PLACEBO-CONTROLLED GO-RAISE STUDY. Clinical and Experimental Rheumatology. 28(4). 618–618. 6 indexed citations
16.
Braun, Jürgen, Xenofon Baraliakos, Joachim Listing, et al.. (2007). Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti–tumor necrosis factor α agents. Arthritis Care & Research. 57(4). 639–647. 145 indexed citations
17.
Sieper, Joachim & Martín Rudwaleit. (2005). Frühdiagnose rheumatischer Erkrankungen—: Relevanz und Herausforderung. Zeitschrift für Rheumatologie. 64(8). 513–515.
18.
Sieper, Joachim, et al.. (2005). How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?. Annals of the Rheumatic Diseases. 64. iv61–iv64. 26 indexed citations
19.
Braun, Jürgen, Joachim Sieper, Maxime Bréban, et al.. (2002). Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience. Annals of the Rheumatic Diseases. 61. iii51–iii60. 46 indexed citations
20.
Braun, Jürgen, et al.. (1994). Three-colour flowcytometric examination of CD4/CD45 subsets reveals no differences in peripheral blood and synovial fluid between patients with reactive arthritis and rheumatoid arthritis.. PubMed. 12(1). 17–22. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jürgen Braun Breakdown of academic impact, for papers by Walter P. Maksymowych Breakdown of academic impact, for papers by Martín Rudwaleit Breakdown of academic impact, for papers by Jane G. Schaller Breakdown of academic impact, for papers by Robert D. Inman Breakdown of academic impact, for papers by John D. Reveille Breakdown of academic impact, for papers by Dominique Baeten Breakdown of academic impact, for papers by Larry W. Moreland Breakdown of academic impact, for papers by Thomas A. Medsger Breakdown of academic impact, for papers by Ricard Cervera
Rankless by CCL
2026